HER2-positive breast cancer patients prefer faster subcutaneous administration of Herceptin® (trastuzumab) to IV
Results from the PrefHer (Patient Preference for Subcutaneous (SC) versus Intravenous (IV) Herceptin) trial show that 92% of early HER2-positive breast cancer patients favoured quicker SC administration of Herceptin compared to the standard IV infusion.
Life-saving tests for cancer are refused, in The Sunday Express
The Sunday Express newspaper reports on Dr Valerie Jenkins talking about the underrecognition of the symptoms of ovarian cancer and the lack of required treatment services.
AChEW featured in Daily Mail
The Adjuvant Chemotherapy in Elderly Women (AChEW) study has been featured today in The Daily Mail's article, "Breast cancer betrayal of older women - only one in seven over 70s are given chemotherapy".
Read about this news item on University of Sussex website
Grant success for SHORE-C
- TARGIT B: Professor Lesley Fallowfield has been awarded a grant from National Institute for Health Research (NIHR) to run a quality of life sub study for TARGIT B. The randomised controlled trial has been designed to evaluate whether a tumour boost in the form of a single fraction of radiotherapy given intra-operatively and targeted to the tissues at the highest risk of local recurrence is superior to a standard post-operative external beam radiotherapy boost after breast conserving surgery in women with a high risk of local recurrence.
- Progression Free Survival: Professor Lesley Fallowfield has been awarded a grant from Boehringer Ingelheim GMBH for a 3 year study on Progression Free Survival (PFS). The study’s aim is to contribute an empirically derived patient perspective about the use of progression-free survival as an appropriate endpoint in clinical trials of cancer therapy. PFS is the length of time after cancer treatment that a patient lives with the disease without tests showing that it is worsening. Although PFS is used in clinical trials as a means of testing how well a new treatment might work, a longer PFS does not necessarily mean that overall survival is improved. So if patients derive PFS benefits but overall live no longer and they suffer unacceptable side-effects from the treatment then this PFS may be of little value. This is an extremely important study that has generated much interest already.
- Feasibility study to examine breast cancer treatment and cognition: Dr Valerie Jenkins has been awarded a grant from Breast Cancer Campaign to run a pilot study to investigate whether chemotherapy associated changes in brain structure and connectivity, underpin symptoms of cognitive impairment (chemo-brain). The pilot study is a good example of cross disciplinary research at BSMS, involving psychologists at SHORE-C, the Clinical Imaging Sciences Centre (Prof Mara Cercignani & Dr Neil Harrison), experts in molecular cell biology at the Trafford Centre (Dr Sandra Sacre), medicine & immunology (Prof Keven Davies), oncology (Prof Peter Schmid) and the clinical breast team (led by consultant surgeon Mr Zammit).
More on the Brighton and Sussex Medical School website.
Research conducted by SHORE-C during the ARIX study shows Acupuncture offers relief from the radiotherapy side effect of Xerostomia.
Read the full press release on the University of Sussex website.
Communicating about clinical trials module 1 updated
Module 1 of the series “Communicating about RCTs” has been updated with new material and Professor Lesley Fallowfield presenting results from relevant research studies.
It is an easy to use DVD with separate chapters, so you have more control.
There is a separate step-by-step booklet to accompany the updated DVD.
The DVD is FREE to all who have bought the previous series of training Videos/DVDs.
For your copy, please contact firstname.lastname@example.org.
A video discussion with Professor Lesley Fallowfield at the European Breast Cancer Conference 2012 about PrefHer, a clinical trial to evaluate patient preference for trastuzumab administered subcutaneously or intravenously in patients with HER2-positive early breast cancer:
Richard Smith: Communicating with patients about ductal carcinoma in situ BMJ blog.
A video discussion with Dr. Lesley Fallowfield at the San Antonio Breast Cancer Symposium 2010
Professor Lesley Fallowfield has been awarded the Lifetime Achievement Award as part of the Pfizer Excellence in Oncology Awards 2010.
Celebrating their fifth year, the Awards recognise and reward best practice in oncology management, education and patient care across the UK. They are open to individuals or teams involved in oncology-related patient support, professional education and team initiatives, as well as nursing and medical excellence. The Awards continue to grow and have brought well-deserved recognition to many successful programmes which are advancing cancer care throughout the country.